Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 9
1964 9
1965 3
1966 7
1967 17
1968 19
1969 21
1970 17
1971 28
1972 43
1973 19
1974 37
1975 30
1976 40
1977 34
1978 44
1979 44
1980 50
1981 40
1982 49
1983 57
1984 52
1985 54
1986 44
1987 61
1988 103
1989 169
1990 146
1991 133
1992 132
1993 159
1994 171
1995 204
1996 268
1997 237
1998 273
1999 364
2000 320
2001 336
2002 366
2003 345
2004 405
2005 453
2006 463
2007 507
2008 535
2009 487
2010 538
2011 570
2012 712
2013 727
2014 852
2015 838
2016 934
2017 839
2018 876
2019 920
2020 1123
2021 1229
2022 1212
2023 1085
2024 1134
2025 79

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

19,322 results

Results by year

Filters applied: . Clear all
Page 1
Pancreatic cancer.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Vincent A, et al. Lancet. 2011 Aug 13;378(9791):607-20. doi: 10.1016/S0140-6736(10)62307-0. Epub 2011 May 26. Lancet. 2011. PMID: 21620466 Free PMC article. Review.
Despite developments in detection and management of pancreatic cancer, only about 4% of patients will live 5 years after diagnosis. Survival is better for those with malignant disease localised to the pancreas, because surgical resection at present offers the …
Despite developments in detection and management of pancreatic cancer, only about 4% of patients will live 5 years after diagn …
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. McGuigan A, et al. World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846. World J Gastroenterol. 2018. PMID: 30487695 Free PMC article. Review.
Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. ...Overall, considerable progress is required to reduce the burden associated with pancreatic cancer.
Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis.
Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Cai J, et al. Cancer Lett. 2021 Nov 1;520:1-11. doi: 10.1016/j.canlet.2021.06.027. Epub 2021 Jun 30. Cancer Lett. 2021. PMID: 34216688 Review.
Pancreatic cancer is a malignancy with poor prognosis and high mortality. The recent increase in pancreatic cancer incidence and mortality has resulted in an increased number of studies on its epidemiology. ...Several prediction models for pancreati
Pancreatic cancer is a malignancy with poor prognosis and high mortality. The recent increase in pancreatic cancer
The Role of Immunotherapy in Pancreatic Cancer.
Mukherji R, Debnath D, Hartley ML, Noel MS. Mukherji R, et al. Curr Oncol. 2022 Sep 23;29(10):6864-6892. doi: 10.3390/curroncol29100541. Curr Oncol. 2022. PMID: 36290818 Free PMC article. Review.
While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are s …
While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other maligna …
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Goggins M, et al. Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31. Gut. 2020. PMID: 31672839 Free PMC article.
BACKGROUND AND AIM: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or ge …
BACKGROUND AND AIM: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its cons …
Epidemiology of pancreatic cancer.
Ilic M, Ilic I. Ilic M, et al. World J Gastroenterol. 2016 Nov 28;22(44):9694-9705. doi: 10.3748/wjg.v22.i44.9694. World J Gastroenterol. 2016. PMID: 27956793 Free PMC article. Review.
Cancer of the pancreas remains one of the deadliest cancer types. Based on the GLOBOCAN 2012 estimates, pancreatic cancer causes more than 331000 deaths per year, ranking as the seventh leading cause of cancer death in both
Cancer of the pancreas remains one of the deadliest cancer types. Based on the GLOBOCAN 2012 estimates,
Pancreas Cancer-Associated Pain Management.
Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S; Precision Promise Consortium. Coveler AL, et al. Oncologist. 2021 Jun;26(6):e971-e982. doi: 10.1002/onco.13796. Epub 2021 May 12. Oncologist. 2021. PMID: 33885205 Free PMC article. Review.
Pain is highly prevalent in patients with pancreas cancer and contributes to the morbidity of the disease. Pain may be due to pancreatic enzyme insufficiency, obstruction, and/or a direct mass effect on nerves in the celiac plexus. ...Accordingly, the managem …
Pain is highly prevalent in patients with pancreas cancer and contributes to the morbidity of the disease. Pain may be due to …
Molecular Pathogenesis of Pancreatic Cancer.
Grant TJ, Hua K, Singh A. Grant TJ, et al. Prog Mol Biol Transl Sci. 2016;144:241-275. doi: 10.1016/bs.pmbts.2016.09.008. Epub 2016 Oct 15. Prog Mol Biol Transl Sci. 2016. PMID: 27865459 Free PMC article. Review.
Pancreatic cancers arise predominantly from ductal epithelial cells of the exocrine pancreas and are of the ductal adenocarcinoma histological subtype (PDAC). ...
Pancreatic cancers arise predominantly from ductal epithelial cells of the exocrine pancreas and are of the ductal adenocarcin
Challenges in diagnosis of pancreatic cancer.
Zhang L, Sanagapalli S, Stoita A. Zhang L, et al. World J Gastroenterol. 2018 May 21;24(19):2047-2060. doi: 10.3748/wjg.v24.i19.2047. World J Gastroenterol. 2018. PMID: 29785074 Free PMC article. Review.
Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates which have not improved in the last few decades. Its high mortality rate is attributed to pancreatic cancer biology, difficulty in early diagnosis and the
Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates which have not improved in t
Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines.
van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, van Hooft JE, Besselink MG. van Huijgevoort NCM, et al. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):676-689. doi: 10.1038/s41575-019-0195-x. Epub 2019 Sep 16. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31527862 Review.
Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic neoplasms and other rare cystic lesions, all with different bi
Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that include intraductal papillary muci
19,322 results
You have reached the last available page of results. Please see the User Guide for more information.